MCID: HYP595
MIFTS: 76

Hypertension, Essential

Categories: Genetic diseases, Cardiovascular diseases, Blood diseases, Rare diseases

Aliases & Classifications for Hypertension, Essential

MalaCards integrated aliases for Hypertension, Essential:

Name: Hypertension, Essential 57 13 40
Essential Hypertension 12 76 75 29 55 6 15 73
Hypertension 57 38 76 29 6 3
Hypertension, Salt-Sensitive Essential, Susceptibility to 57 6
Hypertension, Essential, Susceptibility to 57 6
Eht 57 75
Hypertension, Essential, Susceptibility to, 1 57
Hypertension, Essential, Susceptibility to, 2 57
Hypertension, Essential, Susceptibility to, 3 57
Hypertension, Essential, Susceptibility to, 4 57
Hypertension, Essential, Susceptibility to, 5 57
Hypertension, Essential, Susceptibility to, 6 57
Hypertension, Essential, Salt-Sensitive 57
Hypertension, Salt-Sensitive Essential 57
Hypertension, Susceptibility to 57
Hypertension, Essential 1 57
Hypertension, Essential 2 57
Hypertension, Essential 3 57
Hypertension, Essential 4 57
Hypertension, Essential 5 57
Hypertension, Essential 6 57
Idiopathic Hypertension 12
Primary Hypertension 12
Hypertensive Disease 73

Characteristics:

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
multiple genes influence susceptibility to hypertension. candidate genes include angiotensinogen (agt, ), angiotensin receptor-1 (agtr1, ), and beta-3 subunit of guanine nucleotide-binding protein (gnb3, ). susceptibility loci include hyt1 and hyt2 .


HPO:

32
hypertension, essential:
Inheritance multifactorial inheritance


Classifications:



External Ids:

OMIM 57 145500
Disease Ontology 12 DOID:10825
ICD10 33 I10
ICD9CM 35 401 401.9
NCIt 50 C3478
MedGen 42 C0085580

Summaries for Hypertension, Essential

OMIM : 57 The Pickering school held that blood pressure has a continuous distribution, that multiple genes and multiple environmental factors determine the level of one's blood pressure just as the determination of stature and intelligence is multifactorial, and that 'essential hypertension' is merely the upper end of the distribution (Pickering, 1978). In this view the person with essential hypertension is one who happens to inherit an aggregate of genes determining hypertension (and also is exposed to exogenous factors that favor hypertension). The Platt school took the view that essential hypertension is a simple mendelian dominant trait (Platt, 1963). McDonough et al. (1964) defended the monogenic idea. See McKusick (1960) and Kurtz and Spence (1993) for reviews. Swales (1985) reviewed the Platt-Pickering controversy as an 'episode in recent medical history.' The Pickering point of view appears to be more consistent with the observations. (145500)

MalaCards based summary : Hypertension, Essential, also known as essential hypertension, is related to arteries, anomalies of and coronary artery anomaly, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Hypertension, Essential is PTGIS (Prostaglandin I2 Synthase), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and Corticotropin-releasing hormone signaling pathway. The drugs Adcirca and Adempas have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and kidney, and related phenotypes are elevated systolic blood pressure and elevated diastolic blood pressure

UniProtKB/Swiss-Prot : 75 Essential hypertension: A condition in which blood pressure is consistently higher than normal with no identifiable cause.

CDC : 3 High blood pressure is a common and dangerous condition. Having high blood pressure means the pressure of the blood in your blood vessels is higher than it should be. But you can take steps to control your blood pressure and lower your risk of heart disease and stroke.About 1 of 3 U.S. adults—or about 75 million people—have high blood pressure.1Only about half (54%) of these people have their high blood pressure under control.1 This common condition increases the risk for heart disease and stroke, 2 of the leading causes of death for Americans.2Get more quick facts about high blood pressure, or learn more about high blood pressure in the United States.

Disease Ontology : 12 A hypertension with no known cause. It is the most common type of hypertension.

Wikipedia : 76 Essential hypertension (also called primary hypertension or idiopathic hypertension) is the form of... more...

Related Diseases for Hypertension, Essential

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 1
Hypertension, Essential 2 Hypertension, Essential 3
Hypertension, Essential 4 Hypertension, Essential 5
Hypertension, Essential 6 Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Hypertension, Essential via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Related Disease Score Top Affiliating Genes
1 arteries, anomalies of 31.9 AGT AGTR1 NOS3
2 coronary artery anomaly 31.7 AGT AGTR1 MIR155 NOS3
3 chronic kidney failure 31.7 AGT AGTR1 COL4A5 PKD1 PKD2
4 kidney disease 31.6 AGT AGTR1 COL4A5 PKD1 PKD2
5 pre-eclampsia 31.6 AGT AGTR1 NOS2 NOS3
6 myocardial infarction 31.5 ADD1 AGT AGTR1 GNB3 NOS3 PTGIS
7 diabetes mellitus 31.1 AGT AGTR1 MEN1 MIR155 NOS3
8 pulmonary hypertension 30.9 ECE1 NOS2 NOS3 PTGIS
9 pulmonary hypertension, primary, 1 12.5
10 malignant essential hypertension 12.3
11 benign essential hypertension 12.2
12 hypertension, essential 3 12.1
13 hypertension, essential 4 12.1
14 hypertension, essential 5 12.1
15 hypertension, essential 6 12.1
16 hypertension, essential 1 12.1
17 hypertension, essential 2 12.1
18 hypertension, essential 7 12.1
19 hypertension, essential 8 12.1
20 aortic coarctation 11.4 AGT AGTR1 GNB3 NOS3
21 meningococcal infection 11.3 ADD1 AGT AGTR1
22 autosomal dominant polycystic kidney disease 11.3 ADD1 AGT NOS3 PKD1 PKD2
23 end stage renal failure 11.3 AGT AGTR1 COL4A5 PKD1
24 diastolic heart failure 11.3 AGT AGTR1 NOS3
25 orthostatic intolerance 11.3 AGTR1 ECE1 NOS2 NOS3
26 ischemic optic neuropathy 11.3 AGT AGTR1 NOS3
27 mitral valve disease 11.3 AGT AGTR1 NOS3
28 pediatric hypertension 11.3 ADD1 AGT
29 platelet membrane fluidity 11.3 NOS2 NOS3
30 autosomal genetic disease 11.2 MEN1 PKD1 PKD2
31 lymphatic malformations 11.2 PKD1 PKD2
32 multicystic dysplastic kidney 11.2 PKD1 PKD2
33 renal artery disease 11.1 AGTR1 NOS3
34 congenital hepatic fibrosis 11.0 AGTR1 PKD1
35 polycystic kidney disease 3 with or without polycystic liver disease 10.9 PKD1 PKD2
36 nephronophthisis-like nephropathy 1 10.9
37 familial hypertension 10.8 AGT AGTR1
38 endotheliitis 10.5
39 diabetes mellitus, noninsulin-dependent 10.5
40 aging 10.2
41 heart disease 10.1
42 atrial fibrillation 10.0
43 coronary heart disease 1 10.0
44 depression 10.0
45 eclampsia 9.9
46 cerebritis 9.9
47 retinitis 9.9
48 neuronitis 9.9
49 leukemia, acute myeloid 9.9
50 leukemia 9.9

Comorbidity relations with Hypertension, Essential via Phenotypic Disease Network (PDN): (show top 50) (show all 300)


Abducens Nerve Disease Acquired Polycythemia
Active Peptic Ulcer Disease Acute Closed-Angle Glaucoma
Acute Conjunctivitis Acute Cystitis
Acute Ethmoiditis Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Pancreatitis Acute Stress Disorder
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Adrenal Gland Disease Age-Related Hearing Loss
Alcohol Abuse Allergic Rhinitis
Allergic Urticaria Alopecia, Neurologic Defects, and Endocrinopathy Syndrome
Angina Pectoris Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Asthma
Atrioventricular Block Atrophic Gastritis
Atypical Depressive Disorder Auditory System Disease
Autonomic Nervous System Disease Basilar Artery Insufficiency
Bipolar Disorder Bleeding Disorder, Platelet-Type, 11
Blepharitis Borderline Glaucoma
Borderline Personality Disorder Brain Cancer
Brain Compression Brain Edema
Brain Small Vessel Disease with or Without Ocular Anomalies Branch Retinal Artery Occlusion
Bronchitis Buerger Disease
Campylobacteriosis Cardiac Arrest
Cardiac Arrhythmia Central Nervous System Origin Vertigo
Central Retinal Artery Occlusion Central Retinal Vein Occlusion

Graphical network of the top 20 diseases related to Hypertension, Essential:



Diseases related to Hypertension, Essential

Symptoms & Phenotypes for Hypertension, Essential

Symptoms via clinical synopsis from OMIM:

57
Cardiovascular Vascular:
elevated systolic blood pressure
elevated diastolic blood pressure
elevated mean arterial pressure


Clinical features from OMIM:

145500

Human phenotypes related to Hypertension, Essential:

32
# Description HPO Frequency HPO Source Accession
1 elevated systolic blood pressure 32 HP:0004421
2 elevated diastolic blood pressure 32 HP:0005117
3 elevated mean arterial pressure 32 HP:0004972

UMLS symptoms related to Hypertension, Essential:


angina pectoris, chest pain, edema, tremor, equilibration disorder

MGI Mouse Phenotypes related to Hypertension, Essential:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ADD1 AGT AGTR1 ATP1B1 COL4A5 ECE1
2 cardiovascular system MP:0005385 10.11 AGT AGTR1 ATP1B1 COL4A5 ECE1 MEN1
3 mortality/aging MP:0010768 10.07 PKD1 PKD2 ADD1 AGT AGTR1 ATP1B1
4 adipose tissue MP:0005375 9.88 AGT AGTR1 COL4A5 NOS2 NOS3 PKD1
5 muscle MP:0005369 9.7 AGT ATP1B1 ECE1 MEN1 NOS2 NOS3
6 nervous system MP:0003631 9.65 ADD1 AGT AGTR1 ECE1 F12 GNB3
7 renal/urinary system MP:0005367 9.23 NOS3 PKD1 PKD2 PTGIS AGT AGTR1

Drugs & Therapeutics for Hypertension, Essential

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcirca 18 TADALAFIL Eli Lilly May 2009
2
Adempas 18 RIOCIGUAT Bayer Healthcare Pharmaceuticals October 2013
3
Covera-HS 18 VERAPAMIL HYDROCHLORIDE GD Searle, Alza January 1996
4
Letairis 18 AMBRISENTAN Gilead June 2007
5
Opsumit 18 MACITENTAN Actelion Pharmaceuticals October 2013
6
Remodulin 18 TREPROSTINIL United Therapeutics May 2002

Drugs for Hypertension, Essential (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 261)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
3
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145040-37-5 2540
4
Nifedipine Approved Phase 4,Phase 3,Phase 2,Phase 1 21829-25-4 4485
5
Bisoprolol Approved Phase 4 66722-44-9 2405
6
Amiloride Approved Phase 4,Not Applicable 2016-88-8, 2609-46-3 16231
7
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88150-42-9 2162
8
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
9
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 144701-48-4 65999
10
Felodipine Approved, Investigational Phase 4,Phase 3,Not Applicable 72509-76-3 3333
11
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 138402-11-6 3749
12
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 37350-58-6, 51384-51-1 4171
13
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75847-73-3 5362032 40466924
14
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76420-72-9 6917719
15
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-93-5 3639
16
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1 114798-26-4 3961
17
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
18
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83915-83-7, 76547-98-3 5362119
19
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Not Applicable 10102-43-9 145068 160954
20
Metformin Approved Phase 4,Not Applicable 657-24-9 14219 4091
21
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144689-24-7, 144689-63-4 158781 130881
22
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 72956-09-3 2585
23
Spironolactone Approved Phase 4,Phase 3,Phase 2,Not Applicable 1952-01-7, 52-01-7 5833
24
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
25
Chlorthalidone Approved Phase 4,Phase 3 77-36-1 2732
26
Eprosartan Approved Phase 4,Phase 3 133040-01-4 5281037
27
Lercanidipine Approved, Investigational Phase 4,Phase 3,Phase 2 100427-26-7 65866
28
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
29 Lacidipine Approved, Investigational Phase 4,Phase 3 103890-78-4
30
Doxazosin Approved Phase 4,Phase 2,Phase 3 74191-85-8 3157
31
Nebivolol Approved, Investigational Phase 4,Phase 3,Phase 2 152520-56-4, 99200-09-6, 118457-14-0 71301
32
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
33
Allopurinol Approved Phase 4,Phase 2 315-30-0 2094
34
Eplerenone Approved Phase 4,Phase 3,Phase 2,Not Applicable 107724-20-9 150310 443872
35
Hydralazine Approved Phase 4 86-54-4 3637
36 Benidipine Approved, Investigational Phase 4 105979-17-7
37
Indapamide Approved Phase 4,Phase 3 26807-65-8 3702
38
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
39
Spirapril Approved Phase 4 83647-97-6 5311447
40 Manidipine Approved, Investigational Phase 4 89226-50-6
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
42
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 58-05-9 143 6006
43
Serine Approved, Nutraceutical Phase 4,Not Applicable 56-45-1 5951
44 tannic acid Approved, Nutraceutical Phase 4,Phase 3
45
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
46
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
47 Tomato Approved, Nutraceutical Phase 4
48
Candesartan Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 139481-59-7 2541
49
Maleic acid Experimental Phase 4 110-16-7 444266
50
Canrenone Investigational Phase 4 976-71-6 13789

Interventional clinical trials:

(show top 50) (show all 563)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension Unknown status NCT00366119 Phase 4 Ramipril
2 GRK4 Polymorphisms Blood Pressure Response to Candesartan Unknown status NCT01629225 Phase 4 Candesartan
3 A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
4 BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study) Unknown status NCT02398929 Phase 4 Bisoprolol 2.5 mg;Placebo
5 Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension Unknown status NCT02641821 Phase 4 Nifedipine GITS
6 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
7 Combined Antihypertensive Therapy and Sexual Dysfunction Unknown status NCT01238705 Phase 4 Felodipine add Irbesartan;Felodipine add Metoprolol
8 Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure Unknown status NCT02357615 Phase 4 nifedipine CR tablets (Xin Ran);Adalat
9 Treatment of HYpertension: Morning Versus Evening Unknown status NCT02214498 Phase 4 Enalapril/hydrochlorothiazide;Placebo
10 Home Blood Pressure in Hypertension Management Unknown status NCT00841308 Phase 4
11 Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients Unknown status NCT00716950 Phase 4 valsartan/amlodpine;losartan/amlodpine
12 Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension Unknown status NCT02184858 Phase 4 lisinopril, ACE-inhibitor
13 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
14 Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension Unknown status NCT00994617 Phase 4 Losartan and hydrochlorothiazide;Hydrochlorothiazide switched over with Losartan at 8 weeks
15 L-arginine Treatment in Mild Hypertension Unknown status NCT02894723 Phase 4
16 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
17 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
18 Renal Denervation in Hypertension Unknown status NCT01570777 Phase 4
19 Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension Completed NCT01131546 Phase 4 Levamlodipine besylate;Amlodipine maleate
20 Canrenone as Add-on in Patients With Essential Hypertension Completed NCT02687178 Phase 4 Canrenone 50 vs canrenone 100 mg
21 Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension Completed NCT02031861 Phase 4 nifedipine CR tablets (Xin Ran);nifedipine CR tablets (Adalat)
22 The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension Completed NCT00438945 Phase 4 Eprosartan
23 A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R Completed NCT02079805 Phase 4 Azilsartan;Telmisartan
24 Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia Completed NCT02517866 Phase 4 Azilsartan Medoxomil
25 Intensive Vasodilator Therapy in Patients With Essential Hypertension Completed NCT01180413 Phase 4 Amlodipine;Ramipril;Lercanidipine;Losartan
26 Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension Completed NCT01762436 Phase 4 bisoprolol;atenolol
27 Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension Completed NCT00890591 Phase 4 olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
28 Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea Completed NCT00328965 Phase 4 Lacidipine
29 Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension. Completed NCT00654875 Phase 4 Aliskiren;Placebo to Aliskiren
30 A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension Completed NCT03276598 Phase 4 Amlodipine;Bisoprolol;Hydrochlorothiazide;Losartan;Placebo
31 The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy Completed NCT02433119 Phase 4 OROSARTAN® 5/160mg;CODIOVAN® 160/12.5mg
32 A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension Completed NCT01251146 Phase 4 Bisoprolol;Atenolol
33 A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension Completed NCT00631917 Phase 4 Aliskiren;Ramipril
34 Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension Completed NCT00130156 Phase 4 Bunazosin;Doxazosin;Valsartin
35 Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension Completed NCT00473174 Phase 4 Ramipril
36 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
37 A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components Completed NCT00819104 Phase 4 Metoprolol XL 50mg + Amlodipine 5mg;Metoprolol XL 25 mg + Amlodipine 2.5mg;Metoprolol XL 50mg;Metoprolol XL 25 mg;Amlodipine 5mg
38 A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3) Completed NCT01431508 Phase 4 Losartan 50 mg / HCTZ 12.5 mg
39 Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension Completed NCT00861016 Phase 4 metoprolol succinate prolonged-release tablet and felodipine
40 Study of Efficacy and Safety of CVAA489 in Hypertensive Patients Completed NCT02062645 Phase 4 amlodipine/valsartan
41 Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension Completed NCT01518855 Phase 4 Nifedipine (Adalat, BAYA1040);Amlodipine (Norvasc);Diovan
42 Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension Completed NCT02242370 Phase 4 Low dose of telmisartan;High dose of telmisartan
43 Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg Completed NCT00687973 Phase 4 Valsartan/amlodipine 80/5 mg tablets;Amlodipine 5 mg capsules;Amlodipine 10 mg capsules;Atenolol 50 mg tablets;Atenolol 100 mg tablets
44 Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients Completed NCT01042392 Phase 4 Aliskiren;Ramipril;Matching placebo to Aliskiren;Matching placebo to Ramipril
45 China Stroke Primary Prevention Trial Completed NCT00794885 Phase 4 Enalapril/folic acid;Enalapril maleate
46 Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension Completed NCT00765947 Phase 4 Aliskiren;Hydrochlorothiazide;Amlodipine
47 Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) Completed NCT00157963 Phase 4 MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks
48 PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension Completed NCT02058446 Phase 4 Amlodipine/Valsartan
49 Hybrid Blood Pressure Monitor Validation Completed NCT01120990 Phase 4
50 Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension Completed NCT00858702 Phase 4 olmesartan medoxomil and a CCB;olmesartan medoxomil and a diuretic

Search NIH Clinical Center for Hypertension, Essential

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Hypertension, Essential

Genetic tests related to Hypertension, Essential:

# Genetic test Affiliating Genes
1 Essential Hypertension 29 ADD1 AGT AGTR1 ATP1B1 CYP3A5 ECE1 GNB3 NOS2 NOS3 PTGIS RGS5 SELE
2 Hypertension 29

Anatomical Context for Hypertension, Essential

MalaCards organs/tissues related to Hypertension, Essential:

41
Heart, Endothelial, Kidney, Brain, Testes, Liver, Smooth Muscle

Publications for Hypertension, Essential

Articles related to Hypertension, Essential:

(show top 50) (show all 2687)
# Title Authors Year
1
A system view and analysis of essential hypertension. ( 29369145 )
2018
2
Analysis of Association of Angiotensin II Type 1 Receptor Gene A1166C Gene Polymorphism with Essential Hypertension. ( 29371770 )
2018
3
Effects of 12-week brisk walking training on exercise blood pressure in elderly patients with essential hypertension: a pilot study. ( 29363988 )
2018
4
Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. ( 29129575 )
2018
5
Hypomethylation of the Toll-like receptor-2 gene increases the risk of essential hypertension. ( 28560381 )
2017
6
Association of Dopamine D1 and D3 Receptor Gene Polymorphisms with Essential Hypertension in 3 Ethnic Groups in China. ( 28579604 )
2017
7
Hydrochlorothiazide treatment increases the abundance of the NaCl cotransporter in urinary extracellular vesicles of essential hypertensive patients. ( 28274929 )
2017
8
Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. ( 28072551 )
2017
9
Associations between PPARG polymorphisms and the risk of essential hypertension. ( 28727849 )
2017
10
Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension. ( 29121091 )
2017
11
Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. ( 28306636 )
2017
12
Association of endothelin-1 gene polymorphisms with essential hypertension in a Chinese population. ( 28692114 )
2017
13
Circulating miRNA29 family expression levels in patients with essential hypertension as potential markers for left ventricular hypertrophy. ( 28287884 )
2017
14
Association of CYP17A1 Genetic Polymorphisms and Susceptibility to Essential Hypertension in the Southwest Han Chinese Population. ( 28537227 )
2017
15
Positive association between ALDH2 rs671 polymorphism and essential hypertension: A case-control study and meta-analysis. ( 28472173 )
2017
16
I+-Adducin gene promoter DNA methylation and the risk of essential hypertension. ( 28686109 )
2017
17
Associations of CYP4A11 gene-gene and gene-smoking interactions with essential hypertension in the male eastern Chinese Han population. ( 28534704 )
2017
18
A novel haplotype of low-frequency variants in the aldosterone synthase gene among northern Han Chinese with essential hypertension. ( 28953657 )
2017
19
Association between Cullin-3 Single-Nucleotide Polymorphism rs17479770 and Essential Hypertension in the Male Chinese Han Population. ( 28804198 )
2017
20
The Mitochondrial tRNA(Ala) T5655C Mutation May Modulate the Phenotypic Expression of tRNA(Met) and tRNA(Gln) A4401G Mutation in a Han Chinese Family With Essential Hypertension. ( 28111408 )
2017
21
Haplotype-based, case-control study of the receptor (calcitonin) activity-modifying protein (RAMP) 1 gene in essential hypertension. ( 28181496 )
2017
22
Association of NPR3 polymorphism with risk of essential hypertension in a Chinese population. ( 28497617 )
2017
23
Hypomethylation of interleukin-6 (IL-6) gene increases the risk of essential hypertension: a matched case-control study. ( 28300071 )
2017
24
Association of connexin gene polymorphism with essential hypertension in Kazak and Han Chinese in Xinjiang, China. ( 28397038 )
2017
25
Quantitative Serum Proteomic Analysis of Essential Hypertension Using iTRAQ Technique. ( 29201909 )
2017
26
Up-regulation of gap junction in peripheral blood T lymphocytes contributes to the inflammatory response in essential hypertension. ( 28910394 )
2017
27
Association of G-protein I^3 subunit C825T polymorphism with essential hypertension: evidence from 63a88729 subjects. ( 28540932 )
2017
28
Management of Essential Hypertension. ( 28411897 )
2017
29
The ALDH2 gene rs671 polymorphism is not associated with essential hypertension. ( 28613083 )
2017
30
Left atrial volume changes are an early marker of end-organ damage in essential hypertension: A multidisciplinary approach to an old problem. ( 28990216 )
2017
31
Association of NOS3 gene polymorphisms with essential hypertension in Sudanese patients: a case control study. ( 29132319 )
2017
32
Circulating miR-92a expression level in patients with essential hypertension: a potential marker of atherosclerosis. ( 27629245 )
2017
33
Genetic determinants of essential hypertension in the population of Tatars from Russia. ( 28350619 )
2017
34
Effect of Interaction Between Noise and A1166C Site of AT1R Gene Polymorphism on Essential Hypertension in an Iron and Steel Enterprise Workers. ( 28157766 )
2017
35
Relationship between ADD1 Gly460Trp gene polymorphism and essential hypertension in Madeira Island. ( 29049185 )
2017
36
Expression and methylation of circulating microRNA-510 in essential hypertension. ( 27881848 )
2017
37
Association of single nucleotide polymorphisms in the 5' upstream region of the C4BPA gene with essential hypertension in a northeastern Han Chinese population. ( 28627632 )
2017
38
Susceptiveness of Vitamin K epOxide Reductase Complex Subunit 1 Gene Polymorphism in Essential Hypertension. ( 28281786 )
2017
39
Preliminary analysis of the association between methylation of the ACE2 promoter and essential hypertension. ( 28440441 )
2017
40
Interactions between CYP11B2 Promoter Methylation and Smoking Increase Risk of Essential Hypertension. ( 28078278 )
2016
41
A Novel Polymorphism of the CYP19 Gene is Associated with Essential Hypertension in China. ( 27012050 )
2016
42
Longitudinal genome-wide methylation study of Roux-en-Y gastric bypass patients reveals novel CpG sites associated with essential hypertension. ( 27105587 )
2016
43
Reduced Expression of the Extracellular Calcium-Sensing Receptor (CaSR) Is Associated with Activation of the Renin-Angiotensin System (RAS) to Promote Vascular Remodeling in the Pathogenesis of Essential Hypertension. ( 27391973 )
2016
44
Association between the C34T polymorphism of the AMPD1 gene and essential hypertension in Malaysian patients. ( 27323204 )
2016
45
Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. ( 27228432 )
2016
46
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. ( 27502326 )
2016
47
Reduced parasympathetic tone in newly diagnosed essential hypertension. ( 27133323 )
2016
48
Role of tagged SNPs of the AGT gene in causing susceptibility to essential hypertension. ( 27398822 )
2016
49
Synergistic effects of gene polymorphisms of the renin-angiotensin-aldosterone system on essential hypertension in Kazakhs in Xinjiang. ( 26305278 )
2016
50
Association of paraoxonase 1 (PON1) gene polymorphisms and concentration with essential hypertension. ( 27668323 )
2016